智通财经APP获悉，2025年6月4日当天，小米集团-W(01810)、美团-W(03690)、阿里巴巴-W(09988)位 居沪港通(南向)成交额前3位，成交额分别为34.44 亿元、24.70 亿元、23.71 亿元；美团-W(03690)、阿 里巴巴-W(09988)、小米集团-W(01810) 位居深港通(南向)成交额前3位，成交额分别为22.69 亿元、 20.04 亿元、19.96 亿元。 深港通(南向)十大活跃成交公司 公司名称 成交金额 净买入额 美团-W(03690) 22.69 亿元 +8.59 亿元 阿里巴巴-W(09988) 20.04 亿元 +6.58 亿元 小米集团-W(01810) 19.96 亿元 -5.72 亿元 腾讯控股(00700) 19.52 亿元 -7.59 亿元 信达生物(01801) 13.52 亿元 +7053.74 万元 泡泡玛特(09992) 9.42 亿元 +1.55 亿元 中芯国际(00981) 8.49 亿元 -3.25 亿元 比 亚迪股份(01211) 8.46 亿元 +3.94 亿元 石药集团(01093) 7.97 亿元 +3.31 亿元 思摩尔 ...

Group 1: Market Overview - The Hong Kong stock market saw a net inflow of 35.16 billion HKD from Northbound trading on June 4, with 27.74 billion HKD from the Shanghai Stock Connect and 7.42 billion HKD from the Shenzhen Stock Connect [1] - The most bought stocks included Meituan-W (03690), Alibaba-W (09988), and BYD Company (01211), while the most sold stocks were Tencent (00700), Xiaomi Group-W (01810), and SMIC (00981) [1] Group 2: Stock Performance - Meituan-W (03690) recorded a net inflow of 14.13 billion HKD, driven by significant growth in new customers and sales during its recent promotional campaign [6] - Alibaba-W (09988) saw a net inflow of 6.19 billion HKD, with expectations of a 2 trillion RMB market opportunity in instant shopping by 2030 [6] - BYD Company (01211) had a net inflow of 3.93 billion HKD, planning to launch a low-cost micro electric vehicle in Japan and reporting a 15.3% year-on-year increase in May's new energy vehicle sales [7] - Sinopharm Group (01801) received a net inflow of 3.67 billion HKD, presenting promising clinical trial data for its innovative cancer treatment [7] - CSPC Pharmaceutical Group (01093) attracted a net inflow of 3.3 billion HKD, negotiating potential licensing deals worth up to 5 billion USD [8] - Xiaomi Group-W (01810) faced a net outflow of 13.75 billion HKD, with ongoing discussions about its automotive business profitability [8] - Tencent (00700) experienced a net outflow of 14.35 billion HKD, with management indicating that AI product monetization will take several quarters [9]

Group 1 - The Hang Seng Index closed up 0.6%, while the Tech Index rose by 0.57% [1] - Most sectors in the market experienced gains, with significant strength in the consumer and pharmaceutical sectors [1] - Pop Mart (09992.HK) and Mixue Group (02097.HK) both saw their stock prices increase by over 5%, reaching historical highs [1] - Innovent Biologics (01801.HK) experienced a notable rise of over 14% [1]

Group 1 - The market experienced a rebound on June 4, with the ChiNext Index leading the gains. The total trading volume in the Shanghai and Shenzhen markets reached 1.15 trillion yuan, an increase of 11.6 billion yuan compared to the previous trading day [1] - The innovative drug concept remained active, with the Tianhong Innovative Drug ETF (517380) closing up 2.34%, reaching a peak price of 0.660 yuan, the highest since November 2023, and achieving a trading volume of nearly 20 million yuan, a two-year high [1] - The Tianhong Innovative Drug ETF (517380) has seen a year-to-date increase of 25.96% as of June 4, ranking first among all industry ETFs in the market [1] Group 2 - Changjiang Securities indicated that the valuation level of domestic innovative drugs is low, and some products have the potential to be the best in their class globally, supporting the outlook for innovative drugs to expand internationally and achieve premium valuations [2] - Guojin Securities emphasized that innovative drugs and certain semi-innovative drugs are key investment focuses, with upcoming policy changes and data releases expected to catalyze stock price movements [2] - Huafu Securities reported that the total transaction amount for innovative drug BD from 2020 to 2024 increased from 9.2 billion USD to 52.3 billion USD, with the upfront payment amount rising from 600 million USD to 4.1 billion USD [2]

Core Viewpoint - The Hong Kong stock market experienced a slight decline, but the innovative drug sector showed significant movement, with Innovent Biologics surging 17% in a single day, leading to a strong rebound in related ETFs [1] Group 1: Market Performance - The largest thematic ETF in the Hong Kong market, the Hong Kong Innovative Drug ETF (513120), was the most actively traded, with a turnover rate exceeding 38% and a transaction volume close to 40 billion yuan by 11:30 AM [1] - The surge in innovative drugs is attributed to multiple industry catalysts, enhancing market confidence [1] Group 2: Industry Catalysts - The China National Medical Products Administration issued 11 innovative drug approvals at the end of May, boosting expectations for commercialization among pharmaceutical companies [1] - High-quality research results from domestic innovative drugs were showcased at the American Society of Clinical Oncology (ASCO) and American College of Rheumatology (ACR) meetings, validating the value of leading pharmaceutical pipelines and business development capabilities [1] Group 3: Investment Strategy - Investors are encouraged to construct a strategy that includes the Hong Kong Innovative Drug ETF (513120), Medical ETF Leader (560260), and Pharmaceutical and Health ETF (159938) to capture opportunities across the entire innovative drug supply chain [1] - The three ETFs form a closed loop: the Hong Kong Innovative Drug ETF addresses R&D breakthroughs, the Medical ETF Leader focuses on industrialization, and the Pharmaceutical and Health ETF captures commercialization [2] Group 4: ETF Details - The Hong Kong Innovative Drug ETF (513120) tracks the China Securities Hong Kong Innovative Drug Index, with a current P/E ratio of 27 times and a valuation at the 18th percentile historically [4] - The Medical ETF Leader (560260) focuses on medical devices and services, with a P/E ratio of 31 times and a valuation at the 20th percentile historically [4] - The Pharmaceutical and Health ETF (159938) covers the pharmaceutical and health industry, with a P/E ratio of 35 times and a valuation at the 43rd percentile historically [4]

Group 1 - The Hang Seng Index increased by 0.72% during the midday trading session [1] - The Hang Seng Tech Index rose by 1.01% [1] - Innovent Biologics saw a significant increase of over 15% in its stock price [1] Group 2 - Meituan's stock price increased by over 4% [1] - Pop Mart's stock price rose by over 3% [1]

Group 1: Stock Movements in Hong Kong Market - Youqu Holdings (02177) surged over 24% as it actively expands into the health sector with the launch of the Canadian anti-aging health food brand Vanpearl containing ergothioneine [1] - Longfly Fiber Optics (06869) rose nearly 10% following the commencement of mass production at its advanced Wuhan base, successfully producing its first 6-inch silicon carbide wafer [1] - SF Holding (06936) increased over 5% with a reported 19.1% year-on-year growth in express delivery volume in April 2025, reaching 16.32 billion parcels [1] Group 2: Notable Developments in Other Companies - Alibaba Pictures (01060) gained over 4% after announcing a name change to Damai Entertainment, indicating a focus on offline performances and IP derivatives [2] - Innovent Biologics (01801) rose over 4% after presenting promising results for its innovative drug IBI343 for treating advanced pancreatic cancer at the 2025 ASCO annual meeting [2] - Ideal Auto (02015) saw a rise of over 6% with May deliveries reaching 40,856 units, marking a 16.7% year-on-year increase [4] Group 3: U.S. Market Highlights - Ferguson (FERG.US) increased by 2.9% with Q3 sales of $7.621 billion, a 4.3% year-on-year growth, exceeding market expectations [5] - Credo Technology (CRDO.US) surged over 14% with Q4 revenue of $170.3 million, a 179.7% year-on-year increase [6] - Nvidia (NVDA.US) rose by 2.8% as UBS projected significant revenue from a new AI data center project in Texas [6]

Group 1 - The pharmaceutical sector has shown strong performance recently, with the Hang Seng Innovation Drug ETF (159316) and the Hong Kong Stock Connect Pharmaceutical ETF (513200) both experiencing significant gains, tracking indices that rose over 4% [1] - The National Medical Products Administration of China has approved 11 new drugs for market launch, covering various fields including oncology and endocrinology, with several being the "first in China" or "first domestic" in their respective categories [1] - Among the 11 new drugs, 7 are classified as Category 1 drugs, representing the highest level of drug innovation in China's registration classification system [1] Group 2 - Institutions indicate that favorable domestic policies are emerging to encourage high-quality innovation, which may continue to drive rapid growth in corporate performance, with commercial insurance development potentially benefiting the sustained release of innovative products [2] - The valuation levels of domestic innovative drugs are considered low, with some products having the potential to be the best in their global category, suggesting a positive outlook for innovative drugs to enter international markets and achieve premium valuations [2] - The Hang Seng Innovation Drug ETF (159316) tracks the Hang Seng Hong Kong Stock Connect Innovation Drug Index, which includes leading companies in the innovative drug sector listed on the Hong Kong Stock Connect [2]

Group 1 - The Hong Kong stock market saw a broad increase in early trading, with the healthcare sector performing actively, particularly the Hang Seng Healthcare Index ETF (159557) which rose by 3.56% with a turnover rate of 8.1% [1] - Among the constituent stocks, Innovent Biologics surged over 17%, while Zai Lab and China National Pharmaceutical Group both increased by more than 8% [1] - The 2025 American Society of Clinical Oncology (ASCO) annual meeting is highlighted as a significant event, showcasing the latest research from local companies such as Diagreat Pharmaceuticals, Kelun Pharmaceutical, and China National Pharmaceutical Group, with over 70 original research presentations from Chinese researchers [1] Group 2 - Donghai Securities noted that the recent presentation of numerous domestic innovative drug projects at the ASCO meeting indicates the growing international recognition of local innovative pharmaceutical companies, suggesting that innovative drugs are a key investment theme within the healthcare sector [1] - The report emphasizes investment opportunities in sub-sectors such as medical devices, traditional Chinese medicine, chain pharmacies, and medical services [1] - Changjiang Securities pointed out that domestic innovative drugs are currently undervalued, with some products showing potential to be the best in their class globally, supporting the outlook for these drugs to gain international market presence and valuation upside [2]

Core Viewpoint - The Hong Kong innovative drug ETF fund (520700) has shown significant market activity, with a 4.00% increase and a turnover rate exceeding 55.40%, indicating strong investor interest in innovative pharmaceutical stocks [1] Group 1: Company Developments - Innovent Biologics reported promising clinical data for its first-in-class PD-1/IL-2α-bias bispecific antibody fusion protein IBI363 at the 2025 ASCO annual meeting, focusing on advanced non-small cell lung cancer [1] - IBI363 has shown controllable safety and encouraging efficacy trends in squamous non-small cell lung cancer and wild-type lung adenocarcinoma, contributing to long-term survival benefits [1] - At the ASCO conference, Innovent Biologics had a total of 8 oral presentations, accounting for approximately 2% of the total presentations at the event [1] Group 2: Market Analysis - Morgan Stanley has raised its sales forecasts for Innovent's IBI363 and IBI343, citing their significant potential and the likelihood of global development or licensing opportunities [2] - GF Securities emphasizes the value of investing in Hong Kong innovative drugs, noting a shift in market focus from traditional sectors to long-term strategic areas like the Sino-U.S. technology competition [2] - The recent emergence of the DeepSeek large model has positively influenced investor sentiment, leading to a systematic reassessment of China's potential in key technology sectors [2]